Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents

A Healthcare Cost and Resource Utilization Analysis of Intravenous and Oral Agents in the Treatment of Metastatic Renal Cell Carcinoma

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02928263

Enrollment

Registered

2016-10-10

Start date

2017-02-28

Completion date

2017-05-31

Last updated

2017-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Cell Carcinoma

Brief summary

A retrospective study to evaluate healthcare cost and resource utilization for patients with metastatic renal cell carcinoma who have been treated with IV or oral agents

Interventions

OTHERNon-Interventional

Other

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Diagnosis with metastatic renal cell carcinoma * Prescription/administration of one of the IV or oral agents examined in the study

Exclusion criteria

* Patients with other primary cancer diagnosis before RCC diagnosis * Patients with pregnancy or HIV/AIDS

Design outcomes

Primary

Measure	Time frame	Description
Distribution of Healthcare costs for patients treated with oral drugs used in the first-line treatment of Metastatic renal cell carcinoma (mRCC)	Up to 63 months	All-cause healthcare costs will be calculated in the first-line oral cohort as per-patient-per-month (PPPM) costs.
Composite of Resource Utilization for patients treated with oral drugs used in the first-line treatment of mRCC	Up to 63 months	Total numbers and rates of inpatient, outpatient, and emergency room visits per patient will be calculated.
Distribution of Healthcare costs for patients treated with IV drugs used in the first-line treatment of mRCC	Up to 63 months	All-cause healthcare costs will be calculated in the first-line IV cohort as per-patient-per-month (PPPM) costs.
Composite of Resource Utilization for patients treated with IV drugs used in the first-line treatment of mRCC	Up to 63 months	Total numbers and rates of inpatient, outpatient, and emergency room visits per patient will be calculated.

Secondary

Measure	Time frame	Description
Medication Possession Ratio (MPR) for patients treated with oral drugs used in the first-line treatment of mRCC	Up to 63 months	MPR will be calculated for each index drug as the ratio of the sum of the total number of days' supply to the total number of days in the follow-up period.
Medication Possession Ratio (MPR) for patients treated with IV drugs used in the first-line treatment of mRCC	Up to 63 months	MPR will be calculated for each index drug as the ratio of the sum of the total number of days' supply to the total number of days in the follow-up period.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026